Advances in targeting signal transduction pathways

James A. McCubrey, Linda S. Steelman, William H. Chappel, Sun Lin Sun, Nicole M. Davis, Stephen L. Abrams, Richard A. Franklin, Lucio Cocco, Camilla Evangelisti, Francesca Chiarini, Alberto M. Martelli, Massimo Libra, Saverio Candido, Giovanni Ligresti, Grazia Malaponte, Maria C. Mazzarino, Paolo Fagone, Marco Donia, Ferdinando Nicoletti, Jerry PoleselRenato Talamini, Jörg Bäsecke, Sanja Mijatovic, Danijela Maksimovic-Ivanic, Michele Milella, Agostino Tafuri, Joanna Dulińska-Litewka, Piotr Laidler, Antonio B. D'Assoro, Lyudmyla Drobot, Kazuo Umezawa, Giuseppe Montalto, Melchiorre Cervello, Zoya N. Demidenko

Research output: Contribution to journalReview articlepeer-review

35 Scopus citations


Over the past few years, significant advances have occurred in both our understanding of the complexity of signal transduction pathways as well as the isolation of specific inhibitors which target key components in those pathways. Furthermore critical information is being accrued regarding how genetic mutations can affect the sensitivity of various types of patients to targeted therapy. Finally, genetic mechanisms responsible for the development of resistance after targeted therapy are being discovered which may allow the creation of alternative therapies to overcome resistance. This review will discuss some ofthe highlights over the past few years on the roles of key signaling pathways in various diseases, the targeting of signal transduction pathways and the genetic mechanisms governing sensitivity and resistance to targeted therapies.

Original languageEnglish (US)
Pages (from-to)1505-1521
Number of pages17
Issue number12
StatePublished - Dec 2012


  • AMPK
  • Akt
  • Cancer stem cells
  • MTOR
  • Metformin
  • PI3K
  • Raf
  • Targeted therapy
  • Therapy resistance

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Advances in targeting signal transduction pathways'. Together they form a unique fingerprint.

Cite this